PO.TB10.08 · 肿瘤生物学
转录组分析揭示浸润性乳腺癌中肌上皮细胞的重编程
Transcriptomic analysis reveals myoepithelial cell reprogramming in invasive breast cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:导管原位癌(DCIS)中的肌上皮细胞(MECs)虽在形态上与正常MECs相似,但表现出独特的功能特性,促进向浸润性乳腺癌的进展。为研究浸润性疾病(IDC)中MEC的改变,我们对来自同一患者标本的IDC内MECs与邻近正常乳腺组织进行了转录组比较。
方法:乳腺癌组织标本获自HCA Houston Healthcare Southeast(德克萨斯州帕萨迪纳)。通过α-平滑肌肌动蛋白(alphaSMA)染色验证浸润性导管癌(IDC)内MEC的存在,并由病理学家确认。七个未经治疗的局部区域浸润性乳腺癌FFPE蜡块被送至BioChain Institute,采用GeoMx数字空间分析仪(DSP,NanoString)进行空间转录组分析。使用H&E染色识别适宜区域,并利用肿瘤和邻近正常组织构建了3 mm核心组织芯片(TMA)。在5 μm的TMA切片上分析MEC转录组,基于alphaSMA、PanCK和Syto13染色选择ROI以区分MECs与间质,并收集索引寡核苷酸用于测序。文库制备后在Illumina NextSeq2000平台上测序。生物信息学分析由The Bioinformatics CRO在R中使用EdgeR、fgsea和clusterProfiler进行,通过标准化、差异表达、基因集富集分析和功能通路分析揭示了肿瘤相关MECs与邻近正常MECs之间的分子差异。
结果:我们的分析揭示了三个主要领域的深刻分子重编程:细胞外基质相互作用、上皮-间质转化和细胞信号传导。关键分子改变包括:(1)17种不同胶原亚型基因的广泛上调,表明活跃的间质重塑;(2)基质金属蛋白酶(MMP2、MMP9、MMP11和MMP14)表达增加,提示基底膜完整性受损;(3)上皮标志物(KRT5、KRT7和KRT14)的显著失调,为类似癌相关成纤维细胞的过渡表型所特有。其他发现包括促肿瘤基因(SPARC、POSTN)和整合素亚基表达升高,以及生长因子信号通路的改变。这些发现虽受样本量和转录组方法的限制,但与先前报道的DCIS相关MECs中肌上皮重编程相关分子改变一致。
结论:这项全面的转录组分析证明了IDC微环境内肌上皮细胞的显著分子可塑性,与从肿瘤抑制功能向肿瘤促进功能的表型转变相一致。
查看英文原文 English abstract
INTRODUCTION: Myoepithelial cells (MECs) in ductal carcinoma in situ (DCIS), although morphologically similar to normal MECs, exhibit distinct functional properties that promote progression to invasive breast cancer. To investigate MEC alterations in invasive disease (IDC), we performed a transcriptomic comparison of MECs within IDC and adjacent normal breast tissues from the same patient specimens.
METHODS: Breast cancer tissue specimens were obtained from HCA Houston Healthcare Southeast (Pasadena, TX). MEC presence within invasive ductal carcinoma (IDC) was validated by alpha-smooth muscle actin (alphaSMA) staining and confirmed by a pathologist. Seven untreated, loco-regional invasive breast carcinoma FFPE blocks were sent to BioChain Institute for spatial transcriptomic profiling using the GeoMx Digital Spatial Profiler (DSP, NanoString). H&E staining was used to identify suitable regions, and a 3 mm core tissue microarray (TMA) was constructed using both tumor and adjacent normal tissues. MEC transcriptomes were profiled on 5 μm TMA sections, with ROIs selected based on alphaSMA, PanCK, and Syto13 staining to distinguish MECs from stroma, and indexing oligonucleotides were collected for sequencing. Libraries were prepared and sequenced on an Illumina NextSeq2000 platform. Bioinformatics analyses were conducted in R by The Bioinformatics CRO using EdgeR, fgsea, and clusterProfiler, with normalization, differential expression, gene set enrichment analysis and functional pathway analysis revealing molecular distinctions between tumor-associated and adjacent normal MECs.
RESULTS : Our analysis revealed profound molecular reprogramming across three principal domains: extracellular matrix interactions, epithelial-mesenchymal transition, and cellular signaling. Key molecular alterations included (1) widespread upregulation of 17 distinct collagen isoform genes, indicating active stromal remodeling; (2) increased expression of matrix metalloproteinases ( MMP2 , MMP9 , MMP11 , and MMP14 ), suggesting compromised basement membrane integrity; and (3) significant dysregulation of epithelial markers ( KRT5 , KRT7 , and KRT14 ), characteristic of a transitional phenotype resembling cancer-associated fibroblasts. Additional findings included elevated expression of pro-tumorigenic genes ( SPARC , POSTN ) and integrin subunits, alongside alterations in growth factor signaling pathways. These findings, although limited by the sample size and the transcriptomic approach, align with previously reported molecular alterations associated with myoepithelial reprogramming in DCIS-associated MECs.
CONCLUSION: This comprehensive transcriptomic analysis demonstrates significant molecular plasticity of myoepithelial cells within the IDC microenvironment, consistent with a phenotypic transition from tumor-suppressive to tumor-promoting function.
利益披露 Disclosure
M. M. Haq, None.
C. Benson,
The Bioinformatics CRO Employment.
M. Kunz,
The Bioinformatics CRO Other, Consultant.
E. Cheung,
BioChain Institute Inc. Employment.